- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Patent holdings for IPC class A61K 31/53
Total number of patents in this class: 3480
10-year publication summary
|
268
|
258
|
237
|
203
|
227
|
269
|
280
|
300
|
259
|
56
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
136 |
| Shionogi & Co., Ltd. | 914 |
71 |
| Novartis AG | 11238 |
49 |
| Janssen Pharmaceutica N.V. | 3839 |
45 |
| Gilead Sciences, Inc. | 1879 |
38 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
36 |
| Servier Pharmaceuticals, LLC | 95 |
35 |
| Incyte Corporation | 918 |
34 |
| Takeda Pharmaceutical Company Limited | 2961 |
32 |
| Bayer Pharma AG | 1096 |
30 |
| The Regents of the University of California | 18943 |
29 |
| Bayer Intellectual Property GmbH | 2671 |
28 |
| Blueprint Medicines Corporation | 194 |
26 |
| GW Research Limited | 402 |
26 |
| AstraZeneca AB | 3042 |
24 |
| F. Hoffmann-La Roche AG | 7958 |
23 |
| Merck Sharp & Dohme Corp. | 2247 |
22 |
| Incyte Holdings Corporation | 609 |
22 |
| Merck Sharp & Dohme LLC | 3689 |
21 |
| Genentech, Inc. | 3742 |
20 |
| Other owners | 2733 |